How to Read a Peptide Study Without Getting Fooled

One study, on its own, almost never settles a question. But a single carefully chosen study is often all it takes to sell a compound. Here is how we read the research behind a peptide claim when we assign an evidence grade — and where the usual tricks like to hide. None of this is hard. It’s mostly just a few good questions, asked in order.

Who (or what) was actually studied

Start by asking who the study was done on. That one fact sets a ceiling on what the study can tell you.

A dish of cells, or a living body? “In vitro” means the work was done in a lab dish — on cells, not a whole creature. A peptide that does something to cells in a dish hasn’t been shown to do anything in a living body. That kind of study is handy for understanding how something might work, but it isn’t proof of a real effect. (“In vivo,” by contrast, means it was tested in a living body.)
Animals, or people? This is the big one. About 9 in 10 drugs that begin human trials never get approved — usually because they don’t actually work, or aren’t safe enough, in people. The single biggest reason is simply that the drug doesn’t work well at a dose people can tolerate. So a pile of great-looking rat data is a hunch, not a finished answer. On the Codex Scale, a compound tested only in animals tops out at 3 (Animal only) — or 4 (Animal-leaning) if a small human pilot exists.
A story, or a trial? Forum posts and influencer testimonials are not data. Without a comparison group, there’s no way to tell the compound apart from a placebo (a dummy treatment), from people naturally getting better on their own, or from all the other things that person changed at the same time.

How the study was designed

Once you’re looking at studies done in people, the design decides how much weight it carries.

Randomized controlled trial (RCT): People are split into groups by chance — some get the treatment, some get a control (often a placebo). The best ones also use blinding, meaning neither the participants nor the researchers know who got what. Splitting people by chance, and keeping everyone in the dark, is what keeps hope and the placebo effect from coloring the result. Replicated large RCTs are what land a compound at the top of the Codex Scale (grades 8–10).
Observational study: Researchers simply watch what happens; they don’t assign anyone to a treatment. This is good for raising questions, but it’s easy to be misled — the people who choose a treatment tend to differ from the people who don’t, and those differences can fake an effect.
How many people, and for how long? Ten people followed for four weeks can’t tell you about a side effect that hits 1 in 100 people, or about what happens over a year. Small, short, or one-off human trials sit at grades 5–6 on our scale (Early or Preliminary): a hint, not a settled fact.

What was actually measured

A study can be perfectly run and still answer the wrong question. So look closely at what it actually measured (the “endpoint”).

There are two kinds. A surrogate endpoint is a lab number that’s believed to predict a benefit — a hormone level, or a marker on a blood test. A real-world endpoint is whether people actually felt better, functioned better, or lived longer. The FDA itself describes a surrogate as a marker “thought to predict clinical benefit but is not itself a measure of clinical benefit.” And surrogates often don’t pay off: one review of cancer trials found that most surrogate measures lined up only weakly with whether people actually lived longer. In short, “raised IGF-1” or “improved a biomarker” is not the same as “made anyone healthier.”

Who ran it, and where it appeared

Two last checks that catch a lot of hype.

Who paid, and how many labs were involved? Trials funded by the company selling the product are measurably more likely to report good results and upbeat conclusions than independent ones — a large Cochrane review (a respected source that pools many studies) showed exactly this. And when nearly all the positive research on a compound comes from one lab, with no one else able to repeat it, treat it as unconfirmed. We say so plainly in our methodology.
Is it really published yet? A preprint is a study posted online before other scientists have checked it (a step called peer review). The site medRxiv warns that preprints “should not be relied on to guide clinical practice.” A company press release is marketing — it may talk up a trial you can’t actually read, with no methods, no data, and no outside scrutiny. Until there’s a published, peer-reviewed paper you can check for yourself, the claim is only provisional.

Bottom line

Run any peptide study through the same short list of questions. Was it people or animals — in a living body, or a dish? Was it randomized, controlled, and blinded, or just watched from the sidelines? Was it big enough and long enough to mean something? Did it measure a real result, or just a stand-in marker? Who paid for it, did anyone else manage to repeat it, and is it actually published? Those answers are exactly what separate a 9 (Strong) from a 3 (Animal only) from a 1 (Unsupported) on the Codex Scale. When the evidence is thin, the honest thing is to say so — not to round it up into a headline.

Educational content only. Not medical advice.

Sources

New profiles and evidence updates only. No spam, and we never sell or share your email.